Patents by Inventor Steven J. Burakoff

Steven J. Burakoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FKBP-13, an FK506-binding immunophilin
    Patent number: 5498597
    Abstract: A purified preparation of FKBP-13, an FK506- and rapamycin-binding immunophilin; fragments and chimeras of FKBP-13 capable of binding FK506 and/or rapamycin; and DNA molecules encoding such polypeptides.
    Type: Grant
    Filed: January 17, 1992
    Date of Patent: March 12, 1996
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Steven J. Burakoff, Stuart L. Schreiber, Barbara E. Bierer
  • End-blocked peptides inhibiting binding capacity of gp120
    Patent number: 5115098
    Abstract: A C- and N-blocked prolyl-alanine compound having the structure ##STR1## in which X is --OCH.sub.2 --B or ##STR2## in which A and B are hydrogen or phenyl and Y is isobutyl inhibits binding capacity of GP120 and inhibits infection of cells by HIV-1.
    Type: Grant
    Filed: February 28, 1990
    Date of Patent: May 19, 1992
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Steven J. Burakoff, Stuart L. Schreiber
  • Growth inhibitory factor
    Patent number: 4722842
    Abstract: A purified growth inhibitory factor comprising a lipid-like compound derived from or substantially similar to the factor present in lymphocyte or liver cell plasma membranes is capable of inhibiting cytolytic T-lymphocyte killing response and mitogen-induced B cell, T cell, or lymphoid tumor cell proliferation.
    Type: Grant
    Filed: October 11, 1985
    Date of Patent: February 2, 1988
    Assignee: President and Fellows of Harvard College
    Inventors: Kathryn C. Stallcup, Matthew F. Mescher, Steven J. Burakoff